Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Medicinal Chemistry|March 8, 2016
Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived TreatmentsAlberto N Peón, Luis I Terrazas
Mediators of Inflammation|January 18, 2013
Alternatively activated macrophages in types 1 and 2 diabetesArlett Espinoza-Jiménez, Alberto N Peón, Luis I Terrazas
Biomed Research International|March 14, 2013
Immunoregulation by Taenia crassiceps and its antigensAlberto N Peón, Arlett Espinoza-Jiménez, Luis I Terrazas
Medicina (Kaunas, Lithuania)|June 27, 2024
Anti-COVID-19 Vaccination Alters the Menstrual Cycle and Dose Accumulation Enhances the EffectHospital Español de Pachuca Research Group, Roque D Licona-Meníndez, Alberto N Peón
Mediators of Inflammation|May 16, 2020
Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive ApproachesCésar Daniel Sánchez-Hernández, Lucero Aidé Torres-Alarcón, Ariadna González-Cortés, et al.
Mediators of Inflammation|July 27, 2017
Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive MicroenvironmentAlberto N Peón, Yadira Ledesma-Soto, Jonadab E Olguín, et al.
Journal of Neuropathology and Experimental Neurology|December 31, 2019
Intranasal Methylprednisolone Effectively Reduces Neuroinflammation in Mice With Experimental Autoimmune EncephalitisDunia Rassy, Brandon Bárcena, Iván Nicolás Pérez-Osorio, et al.
Frontiers in Microbiology|December 16, 2020
Nanoparticle-Based Devices in the Control of Antibiotic Resistant BacteriaMario F Gómez-Núñez, Mariel Castillo-López, Fernando Sevilla-Castillo, et al.
Biomed Research International|March 18, 2021
Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill PatientsFernando Sevilla-Castillo, Oscar J Roque-Reyes, Fernanda Romero-Lechuga, et al.
Scientific Reports|October 6, 2021
Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric studyAlejandro Durán-Méndez, Alma Delia Aguilar-Arroyo, Emiliano Vivanco-Gómez, et al.
Pageof 2